Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:26 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,634 matching trials from the live ClinicalTrials.gov search.
Filters: Los Angeles, California Clear all
Completed Phase 2 Interventional Results available

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

NCT01222715
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 29 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
163
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Nov 3, 2026, 4:26 PM EST
Recruiting Phase 3 Interventional

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

NCT06380517
View directory record Official record
Conditions
Amblyopia
Interventions
Luminopia, Eye Patch
Device · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years to 7 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
72
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 4:26 PM EST
Terminated Phase 1 Interventional

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

NCT04965818
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
Interventions
Futibatinib and Binimetinib
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Santa Monica, California • Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 4:26 PM EST
Terminated Not applicable Interventional

Exercise Program During Chemotherapy in Metastatic Colorectal Cancer

NCT03111823
View directory record Official record
Conditions
Stage IV Colorectal Cancer
Interventions
Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Nov 3, 2026, 4:26 PM EST
Completed No phase listed Observational

Evaluation of the Fortilink IBF System With TETRAfuse Technology

NCT03699891
View directory record Official record
Conditions
Cervical and Lumbar Fusion
Interventions
Fortilink IBF System with TETRAfuse Technology
Device
Lead sponsor
RTI Surgical
Industry
Eligibility
Not listed
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Sherman Oaks, California • Lone Tree, Colorado • Boca Raton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 1 Interventional

Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants

NCT00008424
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
45
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Nov 3, 2026, 4:26 PM EST
Not listed No phase listed Observational

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

NCT05961670
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Neer Infrared Spectroscopy
Device
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
1 Hour to 24 Hours
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 3, 2026, 4:26 PM EST
Terminated Phase 1 Interventional Results available

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

NCT04751383
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 3 Interventional Results available

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

NCT03061812
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab tesirine, Topotecan, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Nov 3, 2026, 4:26 PM EST
Active, not recruiting Not applicable Interventional

Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding

NCT02875353
View directory record Official record
Conditions
Delayed Post-Polypectomy Induced Ulcer Hemorrhage
Interventions
Doppler Endoscopic Probe
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Downey, California • Los Angeles, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

NCT00157105
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
5 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

NCT00016965
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ixabepilone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
95
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Nov 3, 2026, 4:26 PM EST
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 4:26 PM EST
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke Before and After Thrombectomy

NCT04061577
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Nov 3, 2026, 4:26 PM EST
Completed Not applicable Interventional Results available

Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves

NCT02119442
View directory record Official record
Conditions
Eisenmenger Syndrome
Interventions
Transcather Valve Implantation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Nov 3, 2026, 4:26 PM EST
Active, not recruiting Phase 2 Interventional Results available

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02179086
View directory record Official record
Conditions
Glioblastoma
Interventions
Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
230
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 4:26 PM EST
Completed No phase listed Observational

Brown Fat Activity and White Fat Accumulation

NCT01517581
View directory record Official record
Conditions
Hodgkins Lymphoma, Non-hodgkins Lymphoma
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
6 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 1 Interventional

Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders

NCT02150681
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Mindfulness-based cognitive therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 1Phase 2 Interventional Results available

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

NCT03303339
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Onvansertib, Cytarabine, Decitabine
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 2 Interventional Results available

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932451
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
140
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

NCT02953639
View directory record Official record
Conditions
Schizophrenia
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Nov 3, 2026, 4:26 PM EST
Completed Phase 2 Interventional

Vinblastine and Methotrexate in Treating Children With Desmoid Tumors

NCT00003019
View directory record Official record
Conditions
Desmoid Tumor
Interventions
methotrexate, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Nov 3, 2026, 4:26 PM EST